Literature DB >> 28913556

High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects.

Nina Friis Bak1, M Bendix2, S Hald2, L Reinert3, M K Magnusson4, J Agnholt2.   

Abstract

PURPOSE: Vitamin D may induce tolerance in the intestinal immune system and has been shown to regulate the phenotype of tolerogenic intestinal dendritic cells (DCs) in vitro. It is unknown whether vitamin D supplementation affects human intestinal DCs in vivo, and we aimed to investigate the tolerability and effect on intestinal CD103+DCs of high-dose vitamin D3 treatment in healthy subjects.
METHODS: Ten healthy subjects received a total of 480,000 IU oral vitamin D3 over 15 days and colonic biopsies were obtained before and after intervention by endoscopy. Lamina propria mononuclear cells (LPMCs) were isolated from the biopsies, stained with DC surface markers and analysed with flow cytometry. Snap-frozen biopsies were analysed with qPCR for DC and regulatory T cell-related genes.
RESULTS: No hypercalcemia or other adverse events occurred in the test subjects. Vitamin D decreased the number of CD103+ DCs among LPMCs (p = 0.006). Furthermore, vitamin D induced mRNA expression of TGF-β (p = 0.048), TNF-α (p = 0.006) and PD-L1 (p = 0.02) and tended to induce IL-10 expression (p = 0.06). Multivariate factor analysis discriminated between pre- and post-vitamin D supplementation with a combined increased qPCR expression of PD1, PD-L1, TGF-β, IL-10, CD80, CD86, FOXP3, NFATc2 and cathelicidin.
CONCLUSION: High-dose vitamin D supplementation is well tolerated by healthy subjects and has a direct effect on the CD103+ DCs, local cytokine and surface marker mRNA expression in the colonic mucosa, suggestive of a shift towards a more tolerogenic milieu.

Entities:  

Keywords:  CD103+ dendritic cells; Intestinal immune system; PD-L1; Vitamin D

Mesh:

Substances:

Year:  2017        PMID: 28913556     DOI: 10.1007/s00394-017-1531-y

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  55 in total

Review 1.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.

Authors:  Anders Dige; Maria K Magnusson; Lena Öhman; Christian Lodberg Hvas; Jens Kelsen; Mary Jo Wick; Jørgen Agnholt
Journal:  Scand J Gastroenterol       Date:  2016-01-19       Impact factor: 2.423

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Geographical variation and incidence of inflammatory bowel disease among US women.

Authors:  Hamed Khalili; Edward S Huang; Ashwin N Ananthakrishnan; Leslie Higuchi; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Gut       Date:  2012-01-11       Impact factor: 23.059

5.  Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity.

Authors:  Nathalie Holmén; Anna Lundgren; Samuel Lundin; Ann-Marie Bergin; Anna Rudin; Henrik Sjövall; Lena Ohman
Journal:  Inflamm Bowel Dis       Date:  2006-06       Impact factor: 5.325

6.  Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells.

Authors:  Martin Hewison; Lisa Freeman; Susan V Hughes; Katie N Evans; Rosemary Bland; Aristides G Eliopoulos; Mark D Kilby; Paul A H Moss; Ronjon Chakraverty
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

7.  Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease.

Authors:  Martin Hewison; Fiona Burke; Katie N Evans; David A Lammas; David M Sansom; Philip Liu; Robert L Modlin; John S Adams
Journal:  J Steroid Biochem Mol Biol       Date:  2007-03       Impact factor: 4.292

8.  Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.

Authors:  Wendy W J Unger; Sandra Laban; Fleur S Kleijwegt; Arno R van der Slik; Bart O Roep
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

9.  Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

Authors:  S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup
Journal:  Aliment Pharmacol Ther       Date:  2010-05-11       Impact factor: 8.171

10.  Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation.

Authors:  M K Magnusson; S F Brynjólfsson; A Dige; H Uronen-Hansson; L G Börjesson; J L Bengtsson; S Gudjonsson; L Öhman; J Agnholt; H Sjövall; W W Agace; M J Wick
Journal:  Mucosal Immunol       Date:  2015-06-17       Impact factor: 7.313

View more
  6 in total

Review 1.  Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis.

Authors:  Wei Zhen Yeh; Melissa Gresle; Vilija Jokubaitis; Jim Stankovich; Anneke van der Walt; Helmut Butzkueven
Journal:  Br J Pharmacol       Date:  2020-08-05       Impact factor: 8.739

Review 2.  Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy.

Authors:  Xiran Lin; Xianmin Meng; Zhiqi Song
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 3.  The Role of Vitamin D in Immune System and Inflammatory Bowel Disease.

Authors:  Zengrong Wu; Deliang Liu; Feihong Deng
Journal:  J Inflamm Res       Date:  2022-05-28

4.  Elevated Levels of 1,25-Dihydroxyvitamin D in Plasma as a Missing Risk Factor for Celiac Disease.

Authors:  Seth Scott Bittker
Journal:  Clin Exp Gastroenterol       Date:  2020-01-08

5.  Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab.

Authors:  Mia Bendix; Anders Dige; Søren Peter Jørgensen; Jens Frederik Dahlerup; Bo Martin Bibby; Bent Deleuran; Jørgen Agnholt
Journal:  Nutrients       Date:  2020-11-30       Impact factor: 5.717

Review 6.  Allergic diseases in infancy II-oral tolerance and its failure.

Authors:  Mathias Hornef; Oliver Pabst; Isabella Annesi-Maesano; Manja Fleddermann; Erika von Mutius; Monika Schaubeck; Alessandro Fiocchi
Journal:  World Allergy Organ J       Date:  2021-11-19       Impact factor: 4.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.